Benzinga | Aug 10, 2020 06:58AM EDT

Protalix BioTherapeutics Q2 EPS $(1.01) Misses $(0.20) Estimate, Sales $10.97M Beat $10.87M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.20) by 405 percent. This is a 1920 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $10.97 million which beat the analyst consensus estimate of $10.87 million by 0.89 percent. This is a 10.45 percent decrease over sales of $12.25 million the same period last year.